v3 Template
O

Odyssey Therapeutics, Inc.

Biotechnology/Pharmaceuticals ~280 employees
Founded
--
Employees (Est.)
~280
14 leaders known
Total Funding
$314.0M
Funding Rounds
2
Last Funding
2025-09-10

About Odyssey Therapeutics, Inc.

Odyssey Therapeutics is dedicated to transforming the standard of care for patients with autoimmune and inflammatory diseases. Their mission is to target upstream signaling nodes and mechanisms, such as those in the innate immune system, to prevent pathological inflammation before it occurs, offering the potential for long-lasting, deep remission in a safe and effective manner.

Products & Services

Pipeline of Therapeutics:A pipeline of small molecule and protein therapeutics designed to precisely target disease pathology, focusing on diseases with significant unmet need and large patient populations.

Specialties

Immune drug discovery Autoimmune and inflammatory disease treatment Upstream immune response targeting Medicinal chemistry Computational chemistry Protein chemistry Structural biology Genetics Pharmacology

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Series D
T: -
FT: Series D
A: 213000000
MR: -
FA: $213 million
FAN: 213000000
D: 2025-09-10
FD: 2025-09-10
6 investors
2 RT: Series C
T: -
FT: Series C
A: 101000000
MR: -
FA: $101 million
FAN: 101000000
D: 2023-12-05
FD: 2023-12-05
22 investors
Series D Latest
2025-09-10
$213.0M
6 investors (Pro only)
Series C 2023-12-05
$101.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

G

Gary D. Glick

Founder, President, and Chief Executive Officer

LinkedIn (Pro only)
C

Christopher Butler

Senior Vice President, Chemistry and Head of Early Discovery

LinkedIn (Pro only)
N

Natalie Dales

Chief of Research Operations and Portfolio Strategy

LinkedIn (Pro only)
L

Luigi Franchi

Senior Vice President, Head of Immunology

J

Jason Haas

Chief Financial Officer

J

Jeffrey Hermes

Executive Vice President, Enabling Sciences

View 11 more team members with Pro

Unlock Full Team Directory

Recent News

Odyssey Therapeutics, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology/Pharmaceuticals
Company Size
~280 employees (est.)

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro